Genomics plc, a 2014 spinout company that is developing an integrated platform to uncover the relationships between genetic variation and human disease, has been appointed as Analysis Partner for the Genomics England Genomics Expert Network for Enterprises (GENE) Consortium.
University spinout OxSight, has reported that in a recent UK-wide trial its smart glasses helped sight impaired and blind people to navigate independently, avoid collisions and see in the dark.
A technology co-developed at the Universities of Oxford and Sao Paulo State University in Brazil will be commercialised by spinout OID (Oxford Impedance Diagnostics), offering the potential for ultrasensitive fast diagnostic tests for a range of diseases.
In conjunction with Shakespeare’s Dead at the Bodleian’s Weston Library: TalkAbout Guides App available 1 July – 18 September 2016, free download for iOs and Android.
The fourth annual Oxford Technology Showcase was held on Wednesday 6th July at Oxford’s Saïd Business School. The event brought together experts and innovators from Oxford University, the Oxford University Hospital Trust and the Oxfordshire region. Over 300 investors, entrepreneurs, healthcare companies, researchers and clinicians attended.
Oxford Nanoimaging -- a University of Oxford spinout -- will commence sales of an elegant desktop optical microscope capable of zooming in on objects as tiny as structures inside living cells. This super-resolution microscope will allow scientists to watch how individual molecules perform chemical reactions in real-time.
One of the most ambitious Oxford spinouts to date is on route to becoming a powerhouse in age-related regenerative medicine, developing drugs which can treat cancer, neurodegenerative diseases, heart failure, macular degeneration and other major age-related conditions
Universal flu vaccine developed at Oxford already showing promise in Phase II clinical trials. Large investment of £10m from Oxford Science Enterprises. Further programs include vaccines to boost cancer immunotherapies.
Oxford spinout EvOx Therapeutics will harness the body’s own precision communications system to deliver drugs to specific parts of the body, with the aim of treating conditions which are currently untreatable including those affecting the brain, as well as autoimmune diseases and cancers.
